Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Niemi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Nervous and Mental Disease|February 1, 1996
Prediction of positive placebo response among chronic schizophrenic outpatientsT Taiminen, E Syvalahti, S Saarijarvi, et al.
BMC Biotechnology|May 28, 2015
Isolation of Mal d 1 and Api g 1 - specific recombinant antibodies from mouse IgG Fab fragment libraries - Mal d 1-specific antibody exhibits cross-reactivity against Bet v 1Jaana Haka, Merja H Niemi, Kristiina Iljin, et al.
International Clinical Psychopharmacology|January 1, 1997
Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophreniaT J Taiminen, E Syvälahti, S Saarijärvi, et al.
Addictive Behaviors|May 9, 1998
Smoking and cognitive deficits in schizophrenia: a pilot studyT J Taiminen, R K Salokangas, S Saarijärvi, et al.
Physical Review Letters|August 8, 2009
Relativistic shock waves in viscous gluon matterI Bouras, E Molnár, H Niemi, et al.
Journal of Molecular Biology|July 16, 2010
A structural insight into the molecular recognition of a (-)-Delta9-tetrahydrocannabinol and the development of a sensitive, one-step, homogeneous immunocomplex-based assay for its detectionMerja H Niemi, Laura Turunen, Timo Pulli, et al.
Acta Psychiatrica Scandinavica|September 1, 1996
Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled studyR K Salokangas, S Saarijärvi, T Taiminen, et al.
The Journal of International Medical Research|January 1, 1997
Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patientsE K Syvälahti, T Taiminen, S Saarijärvi, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Nervous and Mental Disease|February 1, 1996
Prediction of positive placebo response among chronic schizophrenic outpatientsT Taiminen, E Syvalahti, S Saarijarvi, et al.
BMC Biotechnology|May 28, 2015
Isolation of Mal d 1 and Api g 1 - specific recombinant antibodies from mouse IgG Fab fragment libraries - Mal d 1-specific antibody exhibits cross-reactivity against Bet v 1Jaana Haka, Merja H Niemi, Kristiina Iljin, et al.
International Clinical Psychopharmacology|January 1, 1997
Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophreniaT J Taiminen, E Syvälahti, S Saarijärvi, et al.
Addictive Behaviors|May 9, 1998
Smoking and cognitive deficits in schizophrenia: a pilot studyT J Taiminen, R K Salokangas, S Saarijärvi, et al.
Physical Review Letters|August 8, 2009
Relativistic shock waves in viscous gluon matterI Bouras, E Molnár, H Niemi, et al.
Journal of Molecular Biology|July 16, 2010
A structural insight into the molecular recognition of a (-)-Delta9-tetrahydrocannabinol and the development of a sensitive, one-step, homogeneous immunocomplex-based assay for its detectionMerja H Niemi, Laura Turunen, Timo Pulli, et al.
Acta Psychiatrica Scandinavica|September 1, 1996
Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled studyR K Salokangas, S Saarijärvi, T Taiminen, et al.
The Journal of International Medical Research|January 1, 1997
Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patientsE K Syvälahti, T Taiminen, S Saarijärvi, et al.
Pageof 2